X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36) 36
index medicus (34) 34
multiple myeloma (24) 24
hematology (20) 20
oncology (20) 20
bortezomib (16) 16
female (13) 13
male (13) 13
multiple myeloma - drug therapy (12) 12
multiple myeloma - pathology (11) 11
aged (10) 10
middle aged (10) 10
chemotherapy (9) 9
hematology, oncology and palliative medicine (9) 9
cancer (8) 8
dexamethasone (8) 8
leukemia (8) 8
antineoplastic agents - pharmacology (7) 7
apoptosis (7) 7
cell line, tumor (7) 7
multiple-myeloma (7) 7
stem cells (7) 7
treatment outcome (7) 7
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
apoptosis - drug effects (6) 6
cells, cultured (6) 6
flow cytometry (6) 6
survival (6) 6
thalidomide - analogs & derivatives (6) 6
thalidomide - therapeutic use (6) 6
therapy (6) 6
analysis (5) 5
bone marrow (5) 5
carfilzomib (5) 5
cell biology (5) 5
clinical trials (5) 5
cyclophosphamide (5) 5
hemic and lymphatic diseases (5) 5
lenalidomide (5) 5
multiple myeloma - mortality (5) 5
myeloma (5) 5
stem-cell transplantation (5) 5
thalidomide (5) 5
activation (4) 4
care and treatment (4) 4
combination (4) 4
drug resistance, neoplasm (4) 4
drug therapy (4) 4
lymphoma (4) 4
maintenance (4) 4
medical prognosis (4) 4
medicine, research & experimental (4) 4
melphalan (4) 4
multiple myeloma - metabolism (4) 4
research (4) 4
safety (4) 4
therapeutic target (4) 4
transplantation (4) 4
adult (3) 3
aged, 80 and over (3) 3
antigens, cd34 - metabolism (3) 3
autologous transplantation (3) 3
benzamides (3) 3
boronic acids - pharmacology (3) 3
cell proliferation (3) 3
cells (3) 3
chronic lymphocytic-leukemia (3) 3
complete response (3) 3
development and progression (3) 3
diagnosis (3) 3
disease-free survival (3) 3
efficacy (3) 3
endosonography (3) 3
expression (3) 3
gene-expression (3) 3
growth (3) 3
imatinib mesylate (3) 3
immunohistochemistry (3) 3
immunologic factors - therapeutic use (3) 3
immunology (3) 3
in-vitro (3) 3
initial treatment (3) 3
kaplan-meier estimate (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, acute - pathology (3) 3
lymphomas (3) 3
medicine (3) 3
monoclonal gammopathy (3) 3
multiple myeloma - diagnosis (3) 3
multiple myeloma - genetics (3) 3
multiple myeloma - immunology (3) 3
nf-kappa-b (3) 3
non-hodgkins-lymphoma (3) 3
novel agents (3) 3
oxidative stress (3) 3
patients (3) 3
phase-i (3) 3
pomalidomide (3) 3
prednisone (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2012, Volume 131, Issue 9, pp. 2197 - 2203
Journal Article
FRONTIERS IN ONCOLOGY, ISSN 2234-943X, 08/2019, Volume 9, p. 699
There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple Myeloma... 
multiple myeloma | MULTIPARAMETER FLOW-CYTOMETRY | COMPLETE RESPONSE | TIME QUANTITATIVE PCR | PROGNOSTIC VALUE | PLASMA-CELLS | CONSENSUS GUIDELINES | POLYMERASE-CHAIN-REACTION | CIRCULATING TUMOR-CELLS | ONCOLOGY | END-POINT | MRD DETECTION | flow cytometry | minimal residual disease | NGS | liquid biopsy
Journal Article
世界胃肠病学杂志:英文版(电子版), ISSN 1007-9327, 2014, Volume 20, Issue 36, pp. 12993 - 13005
Many progresses have been done in the management of gastrointestinal(GI) lymphomas during last decades, especially after the discovery of Helicobacter... 
lymphomas | Non-Hodgkin | Endoscopy | t | Gastrointestinal | Marginal zone | Non-Hodgkin lymphomas | B-cell lymphomas | Gastrointestinal tract | Endosonography | TISSUE MALT LYMPHOMA | PRIMARY COLONIC LYMPHOMA | CLINICAL-FEATURES | PRIMARY GASTRIC LYMPHOMA | B-CELL LYMPHOMA | HELICOBACTER-PYLORI ERADICATION | NON-HODGKINS-LYMPHOMA | LOW-GRADE | MARGINAL ZONE LYMPHOMA | GASTROENTEROLOGY & HEPATOLOGY | CLINICOPATHOLOGICAL FEATURES | Predictive Value of Tests | Humans | Helicobacter pylori - pathogenicity | Lymphoma, B-Cell, Marginal Zone - therapy | Helicobacter Infections - complications | Stomach Neoplasms - pathology | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - therapy | Neoplasm Grading | Lymphoma, B-Cell, Marginal Zone - pathology | Intestinal Neoplasms - diagnostic imaging | Lymphoma, B-Cell, Marginal Zone - microbiology | Intestinal Neoplasms - microbiology | Stomach Neoplasms - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - pathology | Stomach Neoplasms - therapy | Endoscopy, Gastrointestinal | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - microbiology | Intestinal Neoplasms - pathology | Intestinal Neoplasms - therapy | Stomach Neoplasms - microbiology | Lymphoma, B-Cell, Marginal Zone - diagnostic imaging | Animals | Helicobacter Infections - microbiology | Topic Highlight
Journal Article
Hematological Oncology, ISSN 0278-0232, 04/2019, Volume 37, Issue 2, pp. 117 - 128
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1661-6596, 07/2019, Volume 20, Issue 14, p. 3548
In both monoclonal gammopathy of uncertain significance (MGUS) and multiple myeloma (MM) patients, immune functions are variably impaired, and there is a high... 
CELLS | ACTIVATION | autophagy | BIOCHEMISTRY & MOLECULAR BIOLOGY | BONE-MARROW | PATIENTS TREATED UPFRONT | RISK | INTERLEUKIN-6 | neutrophil | SRC-FAMILY KINASES | CHEMISTRY, MULTIDISCIPLINARY | LYMPHOCYTE RATIO NLR | IFN-gamma | JAK2/STAT3 SIGNALING PATHWAY | STAT-3 | GENERATION | ruxolitinib | IFN-γ
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5669 - 5669
Abstract Background Pomalidomide is a novel immune-modulatory drug approved in Italy in 2015 for double refractory multiple myeloma patients (RRMM), with... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1892 - 1892
Abstract Introduction We have already demonstrated that myeloma mesenchymal stromal cells (MM-MSC) promote cancer immune evasion through the activation of... 
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 02/2017, Volume 13, Issue 5s, pp. 3 - 6
Here we discuss the case of a heavily pretreated male patient with relapsed-refractory multiple myeloma and previous monoclonal gammopathy of undetermined... 
complete response | very good partial response | multiple myeloma | monoclonal gammopathy of undetermined significance | pomalidomide | DEXAMETHASONE | ONCOLOGY | UNDETERMINED SIGNIFICANCE | MONOCLONAL GAMMOPATHY
Journal Article